Randomized Phase II Study to Assess PD 0332991 in Breast Cancer
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase II study trying to identify whether short term treatment with PD0332991
yields anti-proliferative response -defined by a low level of Ki67 expression (IHC) at
surgery- or induces senescence as determined by SABG expression (IHC) in tumors from patients
with early breast cancer non-candidates for neoadjuvant hormonotherapy or chemotherapy, as
compared to no treatment.